Protocol for the Treatment of Metastatic Ewing Sarcoma
Study for the treatment of metastatic Ewing sarcoma with high doses chemotherapy, radiotherapy and maintenance therapy.
Ewing's Sarcoma (ES)
DRUG: TEMIRI|DRUG: ADM|DRUG: IFO|DRUG: CYC|DRUG: ETO|DRUG: BUMEL|DRUG: VIN
Overall Survival (OS), Evaluation of the OS in patients treated according to the protocol, Expected average 3 year|Event Free Survival (DFS), Evaluation of the time in which the patient do not experience any progression, relapse of toxicity event when treated according to the protocol, Expected average 1 year
Safety - Incidence and grade of treatment-emergent Adverse Events, Incidence and grade of treatment-emergent Adverse Events, every 21 days up to 1 year|Evaluation of Quality of life using Pediatric Quality of Life Inventory (PedQL) -in child and adolescents(EORTC QLQ-C30) for children and adolescents, Evaluation of patient's Quality of life: comparison of the Baseline and On treatrment quality of life score using PedQL, every 3 weeks for the first 6 months and 3 monthly up to 1 year|Evaluation of Quality of life using European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients (EORTC QLQ-C30) for adult patients, Evaluation of patient's Quality of life: comparison of the Baseline and On treatrment quality of life score using EORTC QLQ-C30, every 3 weeks for the first 6 months and 3 monthly up to 1 year
Study for the treatment of Ewing metastatic sarcoma with and induction phase with Vincristine (VIN), Adriamycin (ADM), Ciclofosfamide(CYC), Ifosfamide(IFO), Etoposide(ETO) and radiotherapy (RT)followed by a consolidation phase with Busulfan and Melfalan (BUMEL) and Peripheral Blood Stem Cells Transplantation (PBSCT) and a subsequent maintenance phase with Ciclofosfamide and Celecoxib for High Risk (HR) patients.

Very High Risk (VHR) patients will receive a prior frontline therapy with Temozolomide and Irinotecan (TEMIRI), while patient with lung metastasis only will undergo to total lung irradiation after PBSCT